Veronica Wu, founder of First Bight Ventures, recently announced new team members and her hopes for making Houston a leader in synthetic biology. Photo courtesy of First Bight Ventures

Since launching earlier this year, a Houston-based venture capital firm dedicated to investing in synthetic biology companies has made some big moves.

First Bight Ventures, founded by Veronica Wu, announced its growing team and plans to stand up a foundry and accelerator for its portfolio companies and other synthetic biology startups in Houston. The firm hopes to make Houston an international leader in synthetic biology.

“We have a moment in time where we can make Houston the global epicenter of synthetic biology and the bio economy," Wu says to a group of stakeholders last week at First Bight's Rocketing into the Bioeconomy event. "Whether its energy, semiconductor, space exploration, or winning the World Series — Houstonians lead. It’s in our DNA. While others look to the stars, we launch people into space.”

At First Bight's event, Wu introduced the company's new team members. Angela Wilkins, executive director of the Ken Kennedy Institute at Rice University, joined First Bight as partner, and Serafina Lalany, former executive director of Houston Exponential, was named entrepreneur in residence. Carlos Estrada, who has held leadership positions within WeWork in Houston, also joins the team as entrepreneur in residence and will oversee the company's foundry and accelerator that will be established to support synthetic biology startups, Wu says.

“First Bight is investing to bring the best and the brightest — and most promising — synthetic biology startups from around the country to Houston," Wu continues.

First Bighthas one seed-staged company announced in its portfolio. San Diego-based Persephone Biosciences was founded in 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler and Steve Van Dien. The company is working on developing microbial products that impact patient and infant health.

Wu, who worked at Apple before the launch of the iPhone and Tesla before Elon Musk was a household name, says she saw what was happening in Houston after her brother moved to town. She first invested in Houston's synthetic biology ecosystem when she contributed to one of Solugen's fundraising rounds. The alternative plastics company is now a unicorn valued at over $1 billion.

“I founded First Bight because of what I see is the next great wave of technology innovation," she says at the event. "I founded it in Houston because the pieces are right here.”

This week's roundup of Houston innovators includes Erica Sinner of DanceKard, Angela Wilkins of Rice University, and Gina Luna of GP Capital Partners. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from dating tech to investment — recently making headlines in Houston innovation.

Erica Sinner, founder of DanceKard

Houston-based DanceKard is focused on getting singles off the endless swiping in order to make lasting connections and relationships. Photo courtesy of DanceKard

A proud Houstonian, Erica Sinner, whose background is in commercial real estate, was interested in creating a dating app that brought in local businesses. She launched DanceKard with several different offerings — all geared at driving in-person connections. Users can join the app to find events — not necessarily singles-specific events, although those are an option, but meetups where you know a certain number of singles will be in attendance.

"We focus a lot on group dating," Sinner explains. "That's something nobody does."

Singles, along with their single friends, can indicate on the app that they are interested in four, six, or eight-person dates, and see if their are other groups of friends looking to connect. Click here to read more.

Angela Wilkins, executive director of the Ken Kennedy Institute at Rice University

"Better and personalized healthcare through AI is still a hugely challenging problem that will take an army of scientists and engineers." Photo courtesy

Angela Wilkins, executive director of the Ken Kennedy Institute at Rice University, knows data and artificial intelligence can hold bias. It is, after all, designed by humans who have biases whether they know it or not. An issue with this is when these biases affect health care.

"AI presents the opportunity to bring greater personalization to healthcare, but it equally presents the risk of entrenching existing inequalities. We have the opportunity in front of us to take a considered approach to data collection, regulation, and use that will provide a fuller and fairer picture and enable the next steps for AI in healthcare," Wilkins writes in her guest column. Click here to read more.

Gina Luna, partner at GP Capital Partners

Gina Luna joins the Houston Innovators Podcast this week. Photo courtesy of Gina Luna

For most of Gina Luna's career, which includes two decades at JP Morgan before running her own strategic consulting firm, her bread and butter has been working with privately held, lower-middle market companies. Her latest endeavor is no different.

Luna — along with Paul Hobby, and Peter Shaper at Genesis Park — have joined forces to create GP Capital Partners, a new $275 million fund structured as a Small Business Investment Company. The fund will deploy funding into 20 to 25 companies within the region.

"The four of us just thought there was a real opportunity to bring this kind of capital to middle market companies in Houston, Texas, an the Gulf Coast region," Luna says on this week's episode of the Houston Innovators Podcast. "We have already seen, even in the relatively early days, there is a need an an opportunity to invest in great companies, and we are really excited to be doing that." Click here to read more and stream the podcast.

"Better and personalized healthcare through AI is still a hugely challenging problem that will take an army of scientists and engineers." Photo via UH.edu

Houston expert explains health care's inequity problem

guest column

We are currently in the midst of what some have called the "wild west" of AI. Though healthcare is one of the most heavily regulated sectors, the regulation of AI in this space is still in its infancy. The rules are being written as we speak. We are playing catch-up by learning how to reap the benefits these technologies offer while minimizing any potential harms once they've already been deployed.

AI systems in healthcare exacerbate existing inequities. We've seen this play out into real-world consequences from racial bias in the American justice system and credit scoring, to gender bias in resume screening applications. Programs that are designed to bring machine "objectivity" and ease to our systems end up reproducing and upholding biases with no means of accountability.

The algorithm itself is seldom the problem. It is often the data used to program the technology that merits concern. But this is about far more than ethics and fairness. Building AI tools that take account of the whole picture of healthcare is fundamental to creating solutions that work.

The Algorithm is Only as Good as the Data

By nature of our own human systems, datasets are almost always partial and rarely ever fair. As Linda Nordling comments in a Nature article, A fairer way forward for AI in healthcare, "this revolution hinges on the data that are available for these tools to learn from, and those data mirror the unequal health system we see today."

Take, for example, the finding that Black people in US emergency rooms are 40 percent less likely to receive pain medication than are white people, and Hispanic patients are 25 percent less likely. Now, imagine the dataset these findings are based on is used to train an algorithm for an AI tool that would be used to help nurses determine if they should administer pain relief medication. These racial disparities would be reproduced and the implicit biases that uphold them would remain unquestioned, and worse, become automated.

We can attempt to improve these biases by removing the data we believe causes the bias in training, but there will still be hidden patterns that correlate with demographic data. An algorithm cannot take in the nuances of the full picture, it can only learn from patterns in the data it is presented with.

Bias Creep

Data bias creeps into healthcare in unexpected ways. Consider the fact that animal models used in laboratories across the world to discover and test new pain medications are almost entirely male. As a result, many medications, including pain medication, are not optimized for females. So, it makes sense that even common pain medications like ibuprofen and naproxen have been proven to be more effective in men than women and that women tend to experience worse side effects from pain medication than men do.

In reality, male rodents aren't perfect test subjects either. Studies have also shown that both female and male rodents' responses to pain levels differ depending on the sex of the human researcher present. The stress response elicited in rodents to the olfactory presence of a sole male researcher is enough to alter their responses to pain.

While this example may seem to be a departure from AI, it is in fact deeply connected — the current treatment choices we have access to were implicitly biased before the treatments ever made it to clinical trials. The challenge of AI equity is not a purely technical problem, but a very human one that begins with the choices that we make as scientists.

Unequal Data Leads to Unequal Benefits

In order for all of society to enjoy the many benefits that AI systems can bring to healthcare, all of society must be equally represented in the data used to train these systems. While this may sound straightforward, it's a tall order to fill.

Data from some populations don't always make it into training datasets. This can happen for a number of reasons. Some data may not be as accessible or it may not even be collected at all due to existing systemic challenges, such as a lack of access to digital technology or simply being deemed unimportant. Predictive models are created by categorizing data in a meaningful way. But because there's generally less of it, "minority" data tends to be an outlier in datasets and is often wiped out as spurious in order to create a cleaner model.

Data source matters because this detail unquestionably affects the outcome and interpretation of healthcare models. In sub-Saharan Africa, young women are diagnosed with breast cancer at a significantly higher rate. This reveals the need for AI tools and healthcare models tailored to this demographic group, as opposed to AI tools used to detect breast cancer that are only trained on mammograms from the Global North. Likewise, a growing body of work suggests that algorithms used to detect skin cancer tend to be less accurate for Black patients because they are trained mostly on images of light-skinned patients. The list goes on.

We are creating tools and systems that have the potential to revolutionize the healthcare sector, but the benefits of these developments will only reach those represented in the data.

So, what can be done?

Part of the challenge in getting bias out of data is that high volume, diverse and representative datasets are not easy to access. Training datasets that are publicly available tend to be extremely narrow, low-volume, and homogenous—they only capture a partial picture of society. At the same time, a wealth of diverse health data is captured every day in many healthcare settings, but data privacy laws make accessing these more voluminous and diverse datasets difficult.

Data protection is of course vital. Big Tech and governments do not have the best track record when it comes to the responsible use of data. However, if transparency, education, and consent for the sharing of medical data was more purposefully regulated, far more diverse and high-volume data sets could contribute to fairer representation across AI systems and result in better, more accurate results for AI-driven healthcare tools.

But data sharing and access is not a complete fix to healthcare's AI problem. Better and personalized healthcare through AI is still a hugely challenging problem that will take an army of scientists and engineers. At the end of the day, we want to teach our algorithms to make good choices but we are still figuring out what good choices should look like for ourselves.

AI presents the opportunity to bring greater personalization to healthcare, but it equally presents the risk of entrenching existing inequalities. We have the opportunity in front of us to take a considered approach to data collection, regulation, and use that will provide a fuller and fairer picture and enable the next steps for AI in healthcare.

------

Angela Wilkins is the executive director of the Ken Kennedy Institute at Rice University.

Mercury Data Science has taken a tool it originally developed for COVID-19 research and applied it into new areas of research and innovation. Photo via Getty Images

Houston data science company expands pandemic-inspired research tool

by the numbers

Last fall, Houston-based Mercury Data Science released an AI-driven app designed to help researchers unlock COVID-19-related information tucked into biomedical literature. The app simplified access to data about subjects like genes, proteins, drugs, and diseases.

Now, a year into the coronavirus pandemic, Mercury Data Science is applying this technology to areas like agricultural biotech, cancer therapeutics, and neuroscience. It's an innovation that arose from the pandemic but that promises broader, long-lasting benefits.

Angela Holmes, chief operating officer of Mercury Data Science, says the platform relies on an AI concept known as natural language processing (NLP) to mine scientific literature and deliver real-time results to researchers.

"We developed this NLP platform as a publicly available app to enable scientists to efficiently discover biological relationships contained in COVID research publications," Holmes says.

The platform:

  • Contains dictionaries with synonyms to identify things like genes and proteins that may go by various names in scientific literature.
  • Produces data visualizations of relationships among various biological functions.
  • Summarizes the most important data points on a given topic from an array of publications.
  • Depends on data architecture to automate how data is retrieved and processed.

In agricultural biotech, the platform enables researchers to sift through literature to dig up data about plant genetics, Holmes says. The lack of gene-naming standards in the world of plants complicates efforts to search data about plant genetics, she says.


Angela Holmes is the COO of MDS. Photo via mercuryds.com


The platform's ability to easily ferret out information about plant genetics "allows companies seeking gene-editing targets to make crops more nutritious and more sustainable as the climate changes to have a rapid way to de-risk their genomic analyses by quickly assessing what is already known versus what is unknown," Holmes says.

The platform allowed one of Mercury Data Science's agricultural biotech customers to comb through scientific literature about plant genetics to support targeted gene editing in a bid to improve crop yields.

In the field of cancer therapeutics and other areas of pharmaceuticals, the platform helps prioritize drug candidates, Holmes says. One of Mercury Data Science's customers used the platform to extract data from about 2 terabytes (or 2 trillion bytes) of information to evaluate drug candidates. The information included drug studies, clinical trials, and patents. Armed with that data, Mercury Data Science's cancer therapy client signed agreements with new pharmaceutical partners.

The platform also applies to the hunt for biomarkers in neuroscience, including disorders such as depression, anxiety, autism and multiple sclerosis. Data delivered through the platform helps bring new neurobehavioral therapeutics to market, Holmes says.

"An NLP platform to automatically process newly published literature for more insight on the search for digital biomarkers represents a great opportunity to accelerate research in this area," she says.

Mercury Data Science has experience in the field of digital biomarkers, including work for one customer to develop a voice and video platform to improve insights into patients with depression and anxiety in order to improve treatment of those conditions.

The new platform — initially developed as a tool to combat COVID-19 — falls under the startup's vast umbrella of artificial intelligence and data science. Founded in 2017, Mercury Data Science emerged because portfolio companies of the Houston-based Mercury Fund were seeking to get a better handle on AI and data science.

Last April, Angela Wilkins, founder, co-CEO and chief technology officer of Mercury Data Science, left the company to lead Rice University's Ken Kennedy Institute. Dan Watkins, co-founder and managing director of the Mercury Fund, remains at Mercury Data Science as CEO.

The Ken Kennedy Institute fosters collaborations in computing and data. Wilkins replaced Jan Odegard as executive director of the institute. Odegard now is senior director of industry and academic partnerships at The Ion, the Rice-led innovation hub.

Wilkins "is an academic at heart with considerable experience working with faculty and students, and an entrepreneur who has helped build a successful technology company," Lydia Kavraki, director of the Ken Kennedy Institute, said in a news release announcing Wilkins' new role. "Over her career, Angela has worked on data and computing problems in a number of disciplines, including engineering, life sciences, health care, agriculture, policy, technology, and energy."

In honor of International Women's Day on Sunday, here are three female Houston innovators to know this week. Courtesy photos

3 female Houston innovators to know this week

Who's who

In honor of International Women's Day yesterday, today's roundup of Houston innovators features three of the city's entrepreneurs.

From a French ex-pat eliminating cellulite and promoting lymphatic health to a data scientist with a growing company, here are Houston's leading ladies to keep an eye on.

Reda Hicks, founder of GotSpot Inc.

Reda Hicks created GotSpot — a digital tool that helps connect people with commercial space with people who need it. Courtesy of GotSpot

Reda Hicks is a female founder — but more importantly, she supports her fellow female founders. In a lot of ways, its another one of Hicks' side hustles.

This year for SXSW, Hicks, founder of GotSpot — a temporary space finding tool, teamed up with Denise Hamilton, founder of WatchHerWork — a professional women's resource, to create an activation at the festival on March 12 called Texas Female Founders Day, which will feature female founder-focused programming. Despite SXSW being canceled, Texas Female Founders Day will continue.

"The two of us had been to SXSW together for the past two years, and we just saw a whole where a lot of female founders were being lost," Hicks says on this week's episode of the Houston Innovators Podcast. "We can solve both of those problems by creating an experience where it's an entire day that doesn't cost attendees anything and put together a lot of different content that would be really helpful for women growing their business."

Click here to read more.

Angela Wilkins, CTO and co-CEO of Mercury Data Science

It's all a numbers game, and Angela Wilkins of Mercury Data Science is about setting up startups for success. Photo courtesy of MDS

Mercury Fund realized the power of equipping its portfolio companies with data science and artificial intelligence, and the Houston VC fund's first move was to tap data scientist Angela Wilkins to help. The efforts expanded outside Mercury's portfolio, to companies that ranged from early seed stage startups to companies that had raised over $100 million — and they wanted Wilkins' help, either with the basics of data science or execution of analytics.

"In fact, many of the more established companies were sitting on data assets with plans to build AI-enabled products but didn't have the time or people to really start that process," Wilkins says. "After helping a few companies, we realized the need was pretty deep, and bigger than the Mercury Fund portfolio."

Click here to read more.

Emeline Kuhner-Stout, founder of Élastique Athletics

Emeline Kuhner-Stout, founder of Élastique Athletics, wanted to create a product that was easy to wear and benefitted lymphatic health. Photo courtesy of Élastique Athletics

When Emeline Kuhner-Stout was new to Houston, she was a new mom and the only times she had for herself were her daily trips to the gym, and she wanted to make it worth her while.

"There were so many more things I wanted to do for myself, and I just didn't have the time," Kuhner-Stout tells InnovationMap. "It would be so much more efficient if there was a way to combine [elements] to make products that would perform for us."

She got to thinking about creating a product that promoted lymphatic health while being stylish and wearable, so she created Élastique Athletics.

Click here to read more.

It's all a numbers game, and Mercury Data Science is about setting up startups for success. Getty Images

Data-focused Houston company arms startups with the AI tools they need to grow

numbers game

While some say a picture is worth a thousand words, having the right data can be make or break. Houston-based Mercury Data Science is using data and artificial intelligence to paint some really specific pictures for its clients.

MDS was born out of a need for Houston-based Mercury Fund's portfolio companies that wanted a firmer handle on artificial intelligence and data science.

"Three years ago, a number of Mercury Fund portfolio companies and potential investments began to have increasingly important data science and AI components," says Dan Watkins, co-founder and managing director of Mercury Fund. "Mercury's partners wanted a deeper understanding of AI, to understand how the cutting edge meets industry use cases."

Mercury Fund's first move was to tap data scientist Angela Wilkins to lead some training, which then turned into even more workshops and advising. The companies ranged from early seed stage startups to companies that had raised over $100 million — and they wanted Wilkins' help, either with the basics of data science or execution of analytics.

"In fact, many of the more established companies were sitting on data assets with plans to build AI-enabled products but didn't have the time or people to really start that process," Wilkins says. "After helping a few companies, we realized the need was pretty deep, and bigger than the Mercury Fund portfolio."

Wilkins, who serves the company as CTO and co-CEO with Watkins, has seen her efforts grow MDS client base. InnovationMap sat down with Wilkins to see how far MDS has come — and where it's going.

InnovationMap: What sort of problems and data solutions are you providing clients?

Angela Wilkins: We love projects that have a direct impact on human health. In health, we build machine learning driven products to create new forms of digital diagnostics to help improve diagnosis in areas like cognitive functioning and depression. We have helped several therapeutics companies accelerate drug discovery and development by extracting insights from biological and imaging data. We have internal tools that use natural language processing to extract knowledge from millions of scientific publications and patents.

We have also worked quite a bit in consumer behavior and some of our physics-oriented data scientists are now working on noise reduction in geophysics technologies.

IM: What feedback do you get from clients?

AW: Company leaders in every sector are feeling the pressure to gain the advantages of AI or risk falling behind. There are many expert level teams available to Fortune 500 organizations. We are one of the very few teams that is entrepreneurial and agile enough to work with earlier stage, high growth organizations.

IM: How does MDS work with Mercury Fund? Has that relationship evolved over the years?

AW: We continue to work with the Mercury Fund portfolio companies but that is a smaller part of what we do. We are venture backed ourselves, and have now become a Mercury Fund portfolio company, with the same growth ambitions as all venture backed companies.

IM: Recently, MDS has seen some growth. How many employees have you added and are you still hiring?

AW: We are up to 20 employees, mostly data scientists, many with 5 to 8 years of experience working in AI, bioinformatics, and data science to provide insights and build products. We are always looking for great data scientists and data engineers to join our team. We also started a fellowship position for recent graduates, and so we can identify and train the next generation of data scientists

IM: What's been the biggest surprise for you as MDS has grown?

AW: We have been able to create this unique culture that thrives on diversity of thought and background. Half of our team is women. We are solving hard problems that benefit from the creativity you get from a wide variety of views.

IM: Where are MDS clients based?

AW: We have clients from San Francisco to Basel. We have learned how to build an integrated, high communication team with the client, so location is not critical.

That being said, we are active in and committed contributors to the Houston innovation ecosystem. Many of us are from a computational biology and bioinformatics background with deep roots in the Texas Medical Center institutions. Houston has amazing talent and we want to show the data scientists that they don't have to leave Houston to work on interesting problems and continue to build skills at the cutting edge while working for companies all over the world.

IM: What sort of trends are you seeing in venture capital? Are these trends happening in Houston?

We are seeing increasing investments in health AI. Fierce Healthcare reports that health AI topped all other sectors last year with $4B invested into AI startups. Andreesen Horowitz has announced their third and largest biotech and health care fund with $750 million to invest: "Machine learning and artificial intelligence [will] have an outsize impact on how we discover drugs and diagnose disease."

We see similar trends in other areas from industrial software to financial services. The upshot is that the adoption of AI creates significant opportunities for startups and significant challenges for larger companies that are not entrepreneurial and able to build their own data science skill set.

As far as Houston goes, the same trends are there but we tend to lag the major technology hubs in adoption. Efforts like TMC Innovation, Station, Rice University/The Ion and Houston Exponential are having a big impact on both the number and pace of startups and, increasingly, those have AI as a key part of their technology stack.

IM: We've talked about how MDS flies under the radar — why do you think that is? Do you think that'll change as you grow?

AW: Our initial focus was on the work for our clients and on building our team. We are ready to be noticed. Thank you for helping us tell the story with this article.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Deadline extended: InnovationMap, HX open nominations for new combined awards gala

calling all innovators

Update: The deadline for nominations have been extended to midnight on Sunday, October 2.

InnovationMap is back to honor local startups and innovators — and this time, we've upped the ante.

Houston Exponential and InnovationMap have teamed up to combine their annual awards and event efforts to premiere a brand new program. The Houston Innovation Awards Gala on Wednesday, November 9, at The Ion will be a comprehensive event honoring Houston founders, innovators, investors, and more. InnovationMap and HX, which was acquired earlier this year, are in the same network of ownership.

Nominations are open online until midnight October 2, and nominees will have until October 11 to complete an additional application that will be emailed to nominees directly. A group of industry experts and Houston innovation leaders will review those submissions and determine finalists and winners across 11 categories. The categories for this year's awards are:

  • BIPOC-Owned Business honoring an innovative company founded or co-founded by BIPOC representation
  • Female-Owned Business honoring an innovative company founded or co-founded by a woman
  • Hardtech Business honoring an innovative company developing and commercializing a physical technology across life science, energy, space, and beyond
  • B2B Software Business honoring an innovative company developing and programming a digital solution to impact the business sector
  • Green Impact Business honoring an innovative company providing a solution within renewables, climatetech, clean energy, alternative materials, and beyond
  • Smart City Business honoring an innovative company providing a tech solution within transportation, infrastructure, data, and beyond
  • New to Hou honoring an innovative company, accelerator, or investor that has relocated its primary operations to Houston within the past three years
  • DEI Champion honoring an individual who is leading impactful diversity, equity, and inclusion initiatives and progress within Houston and their organization
  • Investor of the Year honoring an individual who is leading venture capital or angel investing
  • Mentor of the Year honoring an individual who dedicates their time and expertise to guide and support to budding entrepreneurs
  • People's Choice: Startup of the Year selected via an interactive voting portal during of the event
Nominees can be submitted to multiple categories.

Additionally, the awards gala will honor an innovator who's made a lasting impact on the Houston innovation community. While you may nominate an individual for the Trailblazer Award via the online form, the judging committee will not require applications or nominations for this category and will be considering potential honorees from the ecosystem at large. If you are interested in sponsorship opportunities, please reach out to cbuckner@houstonexponential.org.

Last year, InnovationMap introduced its awards program and named 28 finalists and honored the nine winners on September 8. Click here to see more from last year's event.

Tickets for the November 9 event are available online. Early bird tickets will be $60 per person and startup founders will be able to attend for $25.

Click here to submit a nomination or see form below.


Major corporation opens hub for global decarbonization in Houston

seeing green

Management consulting giant McKinsey & Co. plans to spend $100 million over the next decade to pump up Houston’s decarbonization economy.

McKinsey says the initiative will, among other things, focus on:

  • Promoting innovations like carbon capture, utilization, and storage (CCUS) and green hydrogen
  • Revamping business models for carbon-heavy companies
  • Ramping up the community of local startups involved in energy transition
  • Developing talent to work on decarbonization

As part of this program, McKinsey has set up a decarbonization hub in its Houston office, at 609 Main St.

“Decarbonization will lead to a new chapter of economic development, while also addressing a critical problem of climate change,” McKinsey partner Nikhil Ati says.

Global decarbonization efforts over the next three decades will require a $100 trillion investment, according to Utility Dive. Houston, home to 40 percent of publicly traded oil and gas companies, stands to gain a substantial share of that opportunity.

McKinsey’s Houston office has worked for several years on Houston’s energy transition initiatives. For instance, the firm helped produce a study and a whitepaper on energy transition here. The whitepaper outlines Houston’s future as the “epicenter of a global clean hydrogen hub.”

“Texas is the nation’s largest renewable energy producer, home to half of the nation’s hydrogen pipelines, and its companies have unparalleled capabilities in building and operating complex projects,” McKinsey senior partner Filipe Barbosa says. “This is Houston’s moment in time on the global stage.”

McKinsey estimates a Houston-based global hub for clean hydrogen that’s in place by 2050 could generate 180,000 jobs and create an economic impact of $100 billion.

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from photonics to robotics — recently making headlines in Houston innovation.

Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship

Brad Burke joins this week's Houston Innovators Podcast. Photo via alliance.rice.edu

Collaboration has made a world of a difference for growing Houston's innovation ecosystem, according to Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship.

"I think Houston has this culture of collaboration that I suspect that some other major cities don't have in the same way," Burke says on the Houston Innovators Podcast. "And while we're a big city, the entrepreneurial ecosystem feels like a small network of a lot of people who work really well together."

Burke has played a major role in the collaboration of Houston for the past 20 years leading the Rice Alliance, which coordinates many event programs and accelerators — including the Rice Business Plan Competition, energy and life science forums, the Clean Energy Accelerator, Owl Spark, Blue Launch, and more. Click here to read more.

Trevor Best, CEO and co-founder of Syzygy Plasmonics

A new partnership for Houston-based Syzygy will generate 1.2 million tons of clean hydrogen each year in South Korea by 2030. Image via Syzygy

Houston-area energy tech startup Syzygy Plasmonics is part of a new partnership that will develop a fully electric chemical reactor for production of clean hydrogen in South Korea.

The reactor will be installed in the second half of 2023 at Lotte Fine Chemical’s facilities in Ulsan, South Korea. Lotte Fine Chemical, Lotte Chemical, and Sumitomo Corporation of Americas are Syzygy’s partners in this venture.

“Simply improving existing tech isn’t enough to reach the world’s decarbonization goals. Stopping climate change will require industries to reimagine what is possible,” Syzygy co-founder and CEO Trevor Best says in a news release. “Our technology expands the accepted paradigms of chemical engineering. We have demonstrated the ability to replace heat from combustion with renewable electricity in the manufacture of foundational chemicals like hydrogen.” Click here to read more.

Nicolaus Radford, CEO and founder of Nauticus Robotics

Houston-based Nauticus Robotics has hit the public market. Image via LinkedIn

Fresh off its September 13 debut as a publicly traded company, Webster-based Nauticus Robotics Inc. is aiming for $90 million in revenue next year as it dives deeper into the ocean economy.

The stock of Nauticus now trades on the NASDAQ market under the ticker symbol KITT. Nauticus went public following its SPAC (special purpose acquisition company) merger with New York City-based CleanTech Acquisition Corp., a “blank check” company that went public in July 2021 through a $150 million IPO. The SPAC deal was valued at $560 million when it was announced in December.

Nauticus continues to be led by CEO Nicolaus Radford and the current executive team.

“The closing of this business combination represents a pivotal milestone in our company’s history as we take public our pursuit of transforming the ocean robotics industry with autonomous systems,” says Radford, who founded what was known as Houston Mechatronics in 2014. “Not only is the ocean a tremendous economic engine, but it is also the epicenter for building a sustainable future.” Click here to read more.